# ANTHEM (ANTHEM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/anthem

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹924.2
- Change: -0.35%
- As of: 2026-09-18
- 1D return: +0.12%
- 5D return: -1.46%
- 1M return: +6.17%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, the stock is trading at ₹928.5, with a generally bullish technical stance across multiple timeframes. Daily, weekly, and monthly indicators suggest an uptrend, with the price trading above key moving averages like the 20-day, 50-day, and 200-day Simple Moving Averages (SMAs), as well as the 20-day and 50-day Exponential Moving Averages (EMAs) and the Supertrend indicator on the daily chart. This alignment across timeframes indicates a strong underlying positive trend. The stock is positioned approximately 88% of the way up its 252-day trading range, suggesting it is trading near its recent highs. However, a "Bearish Engulfing Reversal" pattern was observed on the weekly timeframe on September 18, 2026, which could signal a potential short-term pause or reversal. The stock's annualized volatility stands at 31%, with a current drawdown of -3%.

Nearest support is observed around ₹923.32 (0.56% below the current price), followed by ₹920.0 (0.92% below). Overhead resistance is noted at ₹936.63 (0.88% above the current price), with further levels at ₹942.6 (1.52% above) and ₹945.87 (1.87% above). The recent anomaly on September 18, 2026, showed "high participation no clear direction" on the daily timeframe with an extreme Z-score of 11.89 and a volume ratio of 6.31, indicating significant trading activity without a decisive price move, which warrants close observation.

- The stock's price of ₹928.5 on September 18, 2026, is above its daily, weekly, and monthly Supertrend indicators, supporting a bullish outlook.
- Nearest support levels are ₹923.32 and ₹920.0.
- Nearest resistance levels are ₹936.63 and ₹942.6.
- A "Bearish Engulfing Reversal" pattern was noted on the weekly chart on September 18, 2026.
- Watch for a break below ₹923.32 to test support, or a move above ₹936.63 to challenge resistance.

- Bearish Engulfing Reversal
- Inside Bar
- Evening Star
- Doji
- Harami
- Outside Bar

### News Context

Anthem Biosciences Limited announced on September 8, 2026, the settlement of an upside sharing arrangement valued at approximately ₹1,276.83 million. This settlement, which involved Upside Principal Shareholders Mr. Ajay Bhardwaj, Mr. Ganesh Sambasivam, and Mr. K. Ravindra Chandrappa, followed shareholder approval at the Annual General Meeting on July 22, 2026, and a prior agreement dated December 30, 2024. This development relates to a divestment by Viridity Tone LLP.

Earlier in the week, on July 27, 2026, the company reported its Q1 FY27 results. Consolidated revenues reached ₹418 crores, with the CRDMO segment contributing ₹341 crores and Specialty Ingredients ₹78 crores. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹176 crores, representing a 39.6% margin, and Profit After Tax was ₹120 crores, a 27.1% margin. The company indicated that while underlying demand remains strong, timing shifts in customer deliveries mean a higher concentration of deliveries are expected in the second half of the fiscal year. As of June 30, 2026, the company's net cash position was ₹1,720 crores. The company also held its 20th Annual General Meeting on July 22, 2026, where all presented resolutions, including financial statement adoption and dividend declaration, were passed.

- On September 8, 2026, Anthem Biosciences settled an upside sharing arrangement for approximately ₹1,276.83 million.
- The company reported Q1 FY27 consolidated revenues of ₹418 crores and an EBITDA margin of 39.6% on July 27, 2026.
- Anthem Biosciences noted that customer delivery timing shifts are expected, with more deliveries anticipated in the latter half of the fiscal year.
- As of June 30, 2026, the company's net cash position was ₹1,720 crores.
- The 20th Annual General Meeting was held on July 22, 2026, with all resolutions passed, including the adoption of FY26 financial statements and dividend declaration.

- Anthem Biosciences Limited has informed the Exchange regarding 'Settlement of Upside Sharing Arrangement '. |SUBJECT: Updates

### What Changed

As of September 18, 2026, Anthem Biosciences (ANTHEM) on the NSE has experienced a slight increase in its stock price, moving from ₹927.4 to ₹928.5. This change occurred between the observation date of the previous price and the current report date. No new filings or news developments have been reported recently that would provide additional context for this price movement. The company's profile and listing on the NSE remain unchanged.

- Stock price increased from ₹927.4 to ₹928.5 as of September 18, 2026.
- No new filings or news were reported for Anthem Biosciences as of September 18, 2026.
- The company continues to be listed on the NSE.

### Official Filings

Anthem Biosciences Limited has finalized an upside sharing arrangement, settling approximately ₹1,276.83 million with specific principal shareholders. This settlement follows shareholder approval at the Annual General Meeting on July 22, 2026, and a prior agreement from December 30, 2024, related to a divestment by Viridity Tone LLP. The company also reported its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), ending June 30, 2026. Consolidated revenues reached ₹4,182 million, with the CRDMO segment contributing ₹3,408 million and Specialty Ingredients ₹774 million. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were ₹1,755 million, representing a 39.6% margin, and Profit After Tax (PAT) was ₹1,199 million, with a 27.1% margin. The company noted that timing shifts in customer deliveries affected the quarter, but underlying demand remains strong, with a greater concentration of deliveries anticipated in the second half of the fiscal year. As of June 30, 2026, the company maintained a net cash position of ₹17,197 million. The Board of Directors also approved the allotment of 1,670,909 equity shares under its ESOP Scheme 2024.

- On September 8, 2026, Anthem Biosciences Limited announced the settlement of an upside sharing arrangement for approximately ₹1,276.83 million.
- Shareholder approval for the upside sharing arrangement was obtained at the Annual General Meeting held on July 22, 2026.
- For Q1 FY27 (ended June 30, 2026), consolidated revenues were ₹4,182 million, with EBITDA at ₹1,755 million (39.6% margin) and PAT at ₹1,199 million (27.1% margin).
- The company reported a net cash position of ₹17,197 million as of June 30, 2026.
- On July 21, 2026, the Board approved the allotment of 1,670,909 equity shares under the ESOP Scheme 2024.

- Anthem Biosciences Limited has informed the Exchange regarding 'Settlement of Upside Sharing Arrangement '. |SUBJECT: Updates

### Fundamentals

Anthem Biosciences reported a mixed operating trajectory across recent periods. For the quarter ending June 2026 (Q1 FY27), the company posted Revenue from Operations of ₹418.22 crore, a decrease from ₹610.94 crore in the prior quarter (Q4 FY26). However, Net Profit for Q1 FY27 was ₹119.94 crore, an increase from ₹189.76 crore in Q4 FY26, indicating a potential shift in profitability drivers. The operating profit margin (OPM) for Q1 FY27 stood at 36.0%, compared to 44.0% in Q4 FY26, suggesting some pressure on operational efficiency.

Looking at the balance sheet, the company has managed its debt levels effectively. Borrowings decreased from ₹239 crore in March 2024 to ₹113 crore in March 2025, and are projected to further decrease to ₹54 crore by March 2026. This reduction in debt, coupled with a growing Equity Capital and Reserves, has led to a very low Debt Equity Ratio, reported at 0.0118 in Q1 FY27. The company's cash flow from operations has shown variability, with ₹140.0 crore in March 2024, a projected ₹271.0 crore in March 2025, and a significant increase to ₹844.0 crore by March 2026. Free Cash Flow turned negative in March 2024 at -₹156.0 crore, but is projected to recover to ₹12.0 crore in March 2025 and ₹637.0 crore in March 2026.

Key areas to monitor include the sustainability of the projected increase in operating cash flow, the management of inventory days which have fluctuated significantly, and the impact of increased fixed assets and investments on future returns.

- Revenue from Operations for Q1 FY27 was ₹418.22 crore, a sequential decrease from ₹610.94 crore in Q4 FY26.
- Net Profit for Q1 FY27 was ₹119.94 crore, an increase from ₹92.82 crore in Q3 FY26, but a decrease from ₹189.76 crore in Q4 FY26.
- Operating Profit Margin (OPM) was 36.0% in Q1 FY27, down from 44.0% in Q4 FY26.
- Borrowings have decreased significantly, projected to be ₹54 crore by March 2026 from ₹239 crore in March 2024.
- Free Cash Flow is projected to improve from -₹156.0 crore in March 2024 to ₹637.0 crore by March 2026.

### Bull Case

Anthem Biosciences shows several constructive financial and technical indicators. The company's cash flow from operations has significantly increased, projected to rise from ₹271.0 crore in March 2025 to ₹844.0 crore in March 2026. This growth is reflected in a substantial improvement in free cash flow, expected to jump from ₹12.0 crore to ₹637.0 crore over the same period. Furthermore, the company has demonstrated consistent profit growth, with a compounded profit growth of 17% over 5 years and 18% on a trailing twelve months (TTM) basis. Technically, multiple timeframes (daily, weekly, and monthly) indicate a bullish trend, supported by indicators such as the Supertrend direction and positive Exponential Moving Average (EMA) slopes.

- Cash flow from operations is projected to increase from ₹271.0 crore in March 2025 to ₹844.0 crore in March 2026.
- Free cash flow is expected to grow substantially from ₹12.0 crore in March 2025 to ₹637.0 crore in March 2026.
- The company has achieved a compounded profit growth of 17% over the last 5 years and 18% on a TTM basis.
- Technical indicators across daily, weekly, and monthly timeframes suggest a bullish market trend as of September 18, 2026.

### Bear Case

Anthem Biosciences faces potential headwinds related to its sales performance and investment activities. While profit growth has been robust over the last five years and on a trailing twelve-month (TTM) basis, sales growth has contracted by 2% in the TTM period, contrasting with a 14% compounded growth over five years. This divergence warrants monitoring. Furthermore, the company's cash flow from investing activities has significantly increased from ₹147 crore in March 2025 to ₹702 crore in March 2026, alongside a substantial rise in investments from ₹433 crore to ₹1007 crore over the same periods. This escalation in investment spending, coupled with a notable increase in Cash from Operating Activity from ₹271 crore to ₹844 crore, has resulted in a substantial increase in Free Cash Flow from ₹12 crore to ₹637 crore, but the increased investing outflow has also led to a higher Net Cash Flow of ₹103 crore in March 2026 compared to a negative ₹12 crore in March 2025.

- Sales growth has turned negative, declining by 2% on a TTM basis, compared to a 14% compounded growth over the past five years.
- Investments have more than doubled, increasing from ₹433 crore in March 2025 to ₹1007 crore in March 2026.
- Cash flow used in investing activities has risen sharply, from ₹147 crore in March 2025 to ₹702 crore in March 2026.

### FAQs

**How has Anthem Biosciences' financial position evolved between March 2025 and March 2026?**

Between March 2025 and March 2026, Anthem Biosciences saw significant changes in its balance sheet. Total Assets grew from ₹2,808 crore to ₹3,429 crore. This increase was driven by a substantial rise in Investments, from ₹433 crore to ₹1,007 crore, and an increase in Fixed Assets from ₹705 crore to ₹783 crore. Borrowings decreased from ₹113 crore to ₹54 crore, while Equity Capital remained stable at ₹112 crore. Reserves increased from ₹2,298 crore to ₹2,930 crore. Total Liabilities also grew from ₹2,808 crore to ₹3,429 crore, mirroring the growth in total assets.

**What were the key cash flow activities for Anthem Biosciences in the fiscal years ending March 2025 and March 2026?**

In the fiscal year ending March 2025, Anthem Biosciences reported Cash from Operating Activity of ₹271 crore and Free Cash Flow of ₹12 crore. Cash from Investing Activity was a outflow of ₹147 crore, and Cash from Financing Activity was an outflow of ₹136 crore, resulting in a Net Cash Flow of -₹12 crore. For the fiscal year ending March 2026, there was a significant increase in operating cash flow to ₹844 crore and Free Cash Flow to ₹637 crore. However, Cash from Investing Activity became a larger outflow of ₹702 crore, while Cash from Financing Activity was an outflow of ₹40 crore. This resulted in a positive Net Cash Flow of ₹103 crore.

**What recent corporate announcements have been made by Anthem Biosciences?**

Anthem Biosciences made several recent announcements. On September 8, 2026, the company announced the settlement of an upside sharing arrangement of approximately ₹1,276.83 million. On July 27, 2026, the company reported Q1 FY27 consolidated revenues of ₹418 crores, with EBITDA at ₹176 crores and Profit After Tax at ₹120 crores, noting a net cash position of ₹1,720 crores as of June 30, 2026. The company also held its 20th Annual General Meeting on July 22, 2026, where all resolutions, including the adoption of financial statements for the year ended March 31, 2026, and dividend declaration, were passed. Newspaper advertisements detailing unaudited consolidated and standalone financial results for the quarter ended June 30, 2026, were also published on July 22, 2026.

**What is the recent trading trend and price action for Anthem Biosciences?**

As of September 18, 2026, Anthem Biosciences is trading at ₹928.5. Technical indicators suggest a bullish trend on daily, weekly, and monthly timeframes, with the Supertrend indicator in a bullish direction for all periods. The stock has shown positive returns over various periods, including a 43% return in the last 6 months and a 46% year-to-date return. Nearest resistance levels are observed around ₹936.63 and ₹942.6, while support levels are noted near ₹923.32 and ₹920.0.

- Anthem Biosciences Limited has informed the Exchange regarding 'Settlement of Upside Sharing Arrangement '. |SUBJECT: Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹923.32
- Risk regime: Price Risk Requires Attention

### Support levels
- 920
- 763.05
- 747.471875

### Resistance levels
- 942.6
- 977.55
- 936.6333333333332

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.12% |
| return_10 | -2.34% |
| return_1m | +4.20% |
| return_1y | +8.34% |
| return_20 | +6.17% |
| return_3m | +16.34% |
| return_5 | -1.46% |
| return_6m | +43.20% |
| return_since_start | +27.13% |
| return_ytd | +45.51% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -31.47% |
| annualized_volatility | +30.82% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Drops Sharply, But Profit Margin Holds Above Year-Ago Levels

Anthem Biosciences Limited’s revenue fell sharply in the quarter ended 30 June 2026, reaching its lowest level in five quarters and recording the largest sequential decline in the series. Expenses also contracted, but the net profit margin of 28.68% remained above the year-ago quarter’s level, while the balance sheet carried virtually no debt.

## Revenue and Expenses

Revenue from operations was ₹418.22 crore, down 31.55% from ₹610.94 crore in the previous quarter and down 22.58% from ₹540.21 crore in the same quarter a year ago. The absolute revenue is the lowest among the five quarters shown. The prior year’s pattern showed a dip in Q3 followed by a recovery in Q4, but the current Q1 figure is lower than both the prior Q4 and the year-ago Q1.

Total expenses fell to ₹298.53 crore, a decrease of 22.5% from the prior quarter and 20.77% year‑on‑year. The expense decline was proportionally smaller than the revenue decline, which compressed the operating margin. Employee benefit expense was ₹78.84 crore and depreciation and amortisation was ₹29.99 crore in the current quarter.

## Profitability and Margins

Net profit for the quarter was ₹119.94 crore, down 36.79% from ₹189.76 crore in the previous quarter and down 11.67% from ₹135.79 crore in the year‑ago quarter. The year‑on‑year decline in profit (11.67%) was smaller than the revenue decline (22.58%), indicating that expenses as a proportion of revenue fell.

The net profit margin was 28.68%, above the 25.14% margin of the year‑ago quarter but below the 31.07% margin of the prior quarter. The EBIT margin was 34.78% and the EBITDA margin was 41.95%.

Finance costs were minimal at ₹88.70 lakh, down from ₹1.90 crore in the prior quarter and ₹1.61 crore in the year‑ago quarter. The interest coverage ratio was 164 times, meaning operating earnings far exceeded the quarter’s finance costs.

## Balance Sheet and Leverage

The debt‑equity ratio rose from 0.0002 in Q3 FY2025‑26 to 0.0118 in the current quarter. The absolute level remains extremely low, consistent with a balance sheet that carries virtually no debt. The minimal borrowings support the low finance costs and high interest coverage.

## Segment Revenue

Segment revenue from operations matched total revenue in each quarter for which data is available, which suggests that the company operates as a single reporting segment.

## Earnings Per Share

Basic earnings per share was ₹2.13, down from ₹2.43 in the year‑ago quarter. Diluted EPS was ₹2.11, nearly identical to the basic figure, indicating minimal dilution.

## Key Takeaway

The quarter was marked by a sharp 31.55% sequential decline in revenue — the largest quarterly drop in the five quarters shown — while net profit fell 36.79% from the prior quarter. The net profit margin of 28.68% remained above the year‑ago quarter’s 25.14%, and the company’s minimal debt resulted in an interest coverage ratio of 164 times. The business maintained a solid operating margin, but the top‑line volatility is a notable development.

### Ratios

## Official filings

- 2026-09-08 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_08092026221841_IntimationUpsideSharingSigned.pdf)
- 2026-07-27 — Official Filing: Anthem Biosciences Limited reported Q1 FY27 consolidated revenues of Rs. 418 crores, with CRDMO contributing Rs. 341 crores and Specialty Ingredients Rs. 78 crores. EBITDA was Rs. 176 crores (39.6% margin), and Profit After Tax was Rs. 120 crores (27.1% margin). The company noted timing shifts in customer deliveries, with underlying demand remaining strong and a higher concentration of deliveries expected in the latter half of the year. The net cash position as of June 30, 2026, was Rs. 1,720 crores. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_27072026105731_Earnings_Call_Transcript_Q1_Signed.pdf)
- 2026-07-24 — Generic Announcement: Anthem Biosciences Limited held its 20th Annual General Meeting on July 22, 2026, where all 8 resolutions presented were passed with the requisite majority. These resolutions included the adoption of financial statements for the year ended March 31, 2026, declaration of dividend, re-appointment of a director, appointment of statutory auditors, continuation of an independent director, and approval of commission payable to independent directors, remuneration to related parties, and an upside sharing arrangement with Viridity Tone LLP. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_24072026155625_Voting_Results_Intimation_With_Annexure_numbers.pdf)
- 2026-07-22 — Official Filing: Anthem Biosciences Limited (formerly Anthem Biosciences Private Limited) published newspaper advertisements on July 22, 2026, detailing its unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The advertisements appeared in the Financial Express (English Edition) and Vishwavani (Kannada Edition). The filing was made pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_22072026114914_Newspaper_Publication_Financial_Results_Signed.pdf)
- 2026-07-22 — Official Filing: Anthem Biosciences Limited held its 20th Annual General Meeting on July 22, 2026, via video conference. All resolutions presented, including the adoption of audited financial statements for the year ended March 31, 2026, declaration of dividend, auditor appointments, and approval of various director and remuneration matters, were passed by the members. The company also disclosed its performance for FY 2025-26 and future growth plans. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_22072026234132_AGM_Proceedings_.pdf)
- 2026-07-22 — Official Filing: Anthem Biosciences Limited has made available the audio recording of its earnings call for the quarter ended June 30, 2026. The call, which discussed the unaudited standalone and consolidated financial results, was held on July 22, 2026. The recording can be accessed on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_22072026181542_Investor_Call_Audio_Recoding_Q1_Signed.pdf)
- 2026-07-21 — Earnings Presentation: Anthem Biosciences Limited has revised its Earnings Call Presentation for the quarter ended June 30, 2026. The company reported Q1FY27 revenues of ₹4,182 Mn, with CRDMO contributing ₹3,408 Mn and Specialty Ingredients ₹774 Mn. EBITDA stood at ₹1,755 Mn with a 39.6% margin, and Profit After Tax was ₹1,199 Mn with a 27.1% margin. The net cash position as of June 30, 2026, was ₹17,197 Mn. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_21072026192806_Investor_Presentation_Revised_Signed.pdf)
- 2026-07-21 — Press Release: Anthem Biosciences Limited revised its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹4,182 million, EBITDA of ₹1,755 million with 39.6% margins, and Profit After Tax (PAT) of ₹1,199 million with 27.1% margins for Q1FY27. The Chairman noted timing shifts in deliveries to key customers, with underlying demand remaining strong and a higher concentration of deliveries expected in the latter half of the year. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_21072026192951_Press_Release_Revised_Signed.pdf)
- 2026-07-21 — Official Filing: Anthem Biosciences Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, during their meeting on July 21, 2026. The company also reported the allotment of 1,670,909 equity shares under its ESOP Scheme 2024. The statutory auditors provided an unmodified opinion on these financial results. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_21072026162416_BM_Outcome_Q1_Signed.pdf)
- 2026-07-21 — Official Filing: Anthem Biosciences Limited has released its earnings presentation for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹4,182 Mn, with CRDMO business contributing ₹3,408 Mn and Specialty Ingredients contributing ₹774 Mn. EBITDA stood at ₹1,755 Mn with a margin of 39.6%, and Profit After Tax (PAT) was ₹1,199 Mn with a margin of 27.1%. The net cash position as of June 30, 2026, was ₹17,197 Mn. The Chairman, MD & CEO noted timing shifts in deliveries impacting the quarter but expressed confidence in sustained revenue growth and margin improvement due to cost efficiencies and yield optimization. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_21072026163814_Investor_Call_Presentation_Q1_Signed.pdf)
- 2026-07-21 — Official Filing: Anthem Biosciences Limited reported unaudited consolidated financial results for the quarter ended June 30, 2026. Revenue from operations was ₹4,182 million, with EBITDA at ₹1,755 million (39.6% margin) and Profit After Tax (PAT) at ₹1,199 million (27.1% margin). The company cited timing shifts in deliveries to key customers as a factor in the results, with underlying demand remaining strong. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_21072026164947_Press_Release_Q1_Signed.pdf)
- 2026-07-15 — Generic Announcement: Anthem Biosciences Limited will hold an Earnings Conference Call on Wednesday, July 22, 2026, at 11:30 AM IST to discuss the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The call details are available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_15072026192457_InvestorCallIntimationQ1Signed.pdf)
- 2026-07-10 — Official Filing: Anthem Biosciences Limited, formerly Anthem Biosciences Private Limited, has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The company's Registrar and Transfer Agent, Kfin Technologies Limited, confirmed that details of securities dematerialized/rematerialized during this period have been furnished to all stock exchanges where the company's shares are listed. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_10072026180150_CertificateunderReg74_5_ofDPRegulationsSigned.pdf)
- 2026-07-08 — Generic Announcement: Anthem Biosciences Limited dispatched letters on July 8, 2026, to shareholders without registered email addresses, providing a web link to access the Annual Report for FY 2025-26, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's 20th Annual General Meeting is scheduled for July 22, 2026, to be held via video conferencing. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_08072026122057_Intimationof_Inland_Letter_Sd.pdf)
- 2026-07-08 — Shareholding Disclosure: Anthem Biosciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |SUBJECT: Disclosure under SEBI Takeover Regulations — [Official attachment](https://nsearchives.nseindia.com/corporate/team_bbodade_03072026163037_ANTHEM1.pdf)
- 2026-07-03 — Credit Rating Update: On July 3, 2026, Anthem Biosciences Limited announced that ICRA Limited has revised its credit ratings. The company's Long Term/Short Term Fund Based Working Capital facility of Rs. 175 crore was upgraded to [ICRA]AA (Stable) from [ICRA]AA- (Positive), with the outlook revised to Stable. The Long Term Fund Based Term Loan was also upgraded to [ICRA]AA (Stable) from [ICRA]AA- (Positive). Additionally, a Rs. 10 crore Short Term Non-Fund based facility was assigned [ICRA]A1+. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03072026124318_CreditRatingIntimationSigned.pdf)
- 2026-07-02 — Generic Announcement: Anthem Biosciences Limited clarified discrepancies in its financial results for the quarter and year ended March 31, 2026, submitted on May 19, 2026. The company confirmed the Profit After Tax (PAT) for the financial year 2025-26 is INR 5,917.92 million in both PDF and XBRL filings. The non-disclosure of Consolidated Earnings Per Share (EPS) in the XBRL filing was due to a clerical error, and a revised XBRL filing will be submitted shortly. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_23062026175800_NSE_Financial_Results_Discrepencies_for_FY_25-26_Signed.pdf)
- 2026-07-01 — Generic Announcement: Anthem Biosciences Limited has published newspaper advertisements on July 01, 2026, in the Financial Express and Vishwavani, confirming the dispatch of the Notice for the 20th Annual General Meeting (AGM), along with the Annual Report and e-voting details. This action complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant Ministry of Corporate Affairs and SEBI circulars. The information is also available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_01072026182809_Post_Dispatch_Ad-Final.pdf)
- 2026-06-30 — Generic Announcement: Anthem Biosciences Limited has voluntarily prepared a Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, ahead of the mandatory requirement starting in FY 2026-27. The report, enclosed with an Independent Assurance Statement, covers consolidated disclosures and is available on the company's website. Key disclosures include details on business activities, international markets served (85% exports), employee demographics, and significant investments in technology and sustainability initiatives like renewable energy adoption and water recycling. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_30062026221437_BRSR_Intimation_Final.pdf)
- 2026-06-30 — Generic Announcement: Anthem Biosciences Limited will hold its 20th Annual General Meeting on July 22, 2026, via video conference. The agenda includes adopting financial statements for FY 2025-26, declaring a final dividend of ₹2.00 per equity share, re-appointing K Ravindra Chandrappa as a director, and appointing S.R. Batliboi & Associates LLP as statutory auditors for five years at a remuneration of ₹63,50,000 for FY 2026-27. The meeting will also seek approval for the continuation of Mr. Ravikant Uppal as an independent director beyond age 75 and for commission payable to independent directors, not exceeding 1% of net profits. Additionally, an upside sharing arrangement with Viridity Tone LLP and increased remuneration for related parties will be discussed. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_30062026215752_AGM_Notice_Final.pdf)
- 2026-06-29 — Generic Announcement: Anthem Biosciences Limited has published newspaper advertisements on June 29, 2026, regarding the pre-dispatch intimation of the Notice for its 20th Annual General Meeting (AGM). The AGM is scheduled for July 22, 2026, at 3:30 p.m. IST, and will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The advertisements appeared in the Financial Express (English Edition) and Vishwavani (Kannada Edition). — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_29062026150808_NewspaperPublicationPreDispatchSigned.pdf)
- 2026-06-26 — Generic Announcement: Anthem Biosciences Limited will close its trading window for designated persons from July 01, 2026, until 48 hours after the board meeting to approve financial results for the quarter ending June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_26062026160927_TradingWindowClosureSigned.pdf)
- 2026-06-05 — Generic Announcement: Anthem Biosciences Limited will host a group of investors for a plant visit and meeting on June 10, 2026, in Bangalore. No unpublished price-sensitive information will be discussed during the event. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05062026171645_InvestormeetJune10Signed.pdf)
- 2026-05-22 — Generic Announcement: Anthem Biosciences Limited will participate in the Nomura Investment Forum Asia 2026 in Singapore on June 2nd and 3rd, 2026, and the Citi India Conference 2026 in Mumbai on June 4th and 5th, 2026. Management will engage in one-on-one and group meetings during these events. No unpublished price-sensitive information will be disclosed. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_22052026165444_InvestorCallIntimationJunesigned.pdf)
- 2026-05-22 — Generic Announcement: Anthem Biosciences Limited held an earnings conference call on May 20, 2026, to discuss audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported consolidated revenue of Rs. 2,124 crores for the full year FY26, with an 18% growth over the previous year, and Rs. 611 crores for Q4 FY26, a 26% year-over-year increase. EBITDA for the year was Rs. 990 crores, and Profit After Tax (PAT) was Rs. 592 crores, both showing over 30% growth. The company is investing approximately Rs. 1,200 crores over FY27 and FY28 in Phase 1 of its Unit 4 expansion, aiming to significantly increase custom synthesis and fermentation capacity. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_22052026154836_EarningsCallTranscriptSigned.pdf)

## News and market events

- 2026-09-11 — Mint: **Raja Venkatraman recommends three stocks for 11 September** — Market expert Raja Venkatraman shares his top stock picks for 11 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-11-september-11789058673473.html)
- 2026-09-03 — Mint: **Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Thursday, 3 September** — Indian stock market indices are expected to open higher, following positive global cues. However, previous sessions saw declines in the Sensex and Nifty 50. Global uncertainties related to the US-Iran conflict continue to weigh on market sentiment. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-hints-a-positive-start-eight-day-trading-stocks-to-buy-on-thursday-3-september-11788400588885.html)
- 2026-09-01 — Economic Times: **Anthem Biosciences Share Price Today, Anthem Biosciences Stock Price Live NSE/BSE Updates | The Economic Times** — Anthem Biosciences Share Price Today - Get live NSE/BSE quotes of Anthem Biosciences with latest news, headlines and quick analysis. View forecasts, quarterly results, dividend details, balance sheet & more. — [Source](https://economictimes.indiatimes.com/anthem-biosciences-ltd/stocks/companyid-2248725.cms)
- 2026-08-27 — MONEYCONTROL: **Goldman Sachs-backed CRDMO Aragen Life Sciences files IPO papers to raise Rs 800 crore fresh capital** — Aragen Life Sciences IPO size,Aragen Life Sciences IPO DRHP,Aragen Life Sciences IPO news,Aragen Life Sciences IPO details,Goldman Sachs — [Source](https://www.moneycontrol.com/news/business/ipo/goldman-sachs-backed-crdmo-aragen-life-sciences-files-ipo-papers-to-raise-rs-800-crore-fresh-capital-14017035.html)
- 2026-08-27 — Mint: **Raja Venkatraman recommends three stocks for 27 August** — Market expert Raja Venkatraman shares his top stock picks for 27 August. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-27-august-11787757519206.html)
- 2026-08-27 — Mint: **Stock recommendations for 27 August from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 27 August. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-27-august-marketsmith-india-11787761968102.html)
- 2026-08-21 — CNBC-TV18: **Stocks To Buy: Analysts have a consensus bullish call, Jefferies sees 20% upside** — Anthem Biosciences is a high-growth Indian contract research, development and manufacturing organisation (CRDMO) with industry-leading manufacturing capabilities and a technocrat-led management team. — [Source](https://www.cnbctv18.com/market/anthem-biosciences-share-price-jefferies-says-buy-target-upside-returns-revenue-profit-cagr-19974283.htm)
- 2026-08-21 — Economic Times: **Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target** — Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is bullish on the companys integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29. Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key risks. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/jefferies-initiates-coverage-on-anthem-biosciences-with-a-rs-1050-target/articleshow/133393891.cms)
- 2026-08-03 — MONEYCONTROL: **Trade Spotlight: How should you trade Hero MotoCorp, Anant Raj, Anthem Biosciences, KEI Industries, Escorts, BLS E-Services, and others on August 3?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,BLS E-Services,Hero MotoCorp,Jio Financial Services,Anant Raj,Anthem Biosciences,Blue Jet Healthcare,Shipping Corporation of India,KEI Industries,Escorts Kubota — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-hero-motocorp-anant-raj-anthem-biosciences-kei-industries-escorts-bls-e-services-and-others-on-august-3-13991407.html)
- 2026-07-22 — The Hindu: **Q1 Results LIVE: Nestle PAT up 48% y-o-y, Adani Green, Adani Power, Eternal, Dr Reddy's Lab, NTPC Green, BPCL, HPCL, IndusInd Bank to announce Q1 results today** — Q1 Results Today, 22nd July 2026: Follow our Q1 live updates here — [Source](https://www.thehindubusinessline.com/markets/fy27-q1-results-today-live-updates-adani-green-adani-power-ntpc-nestle-eternal-bpcl-hpcl-indusind-bank-dr-reddys-bajaj-auto-tvs-motor-adani-energy-atgl-mastek-sagility-july-22-2026/article71248906.ece)
- 2026-07-22 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty falls below 24,000 mark as market extends losses** — Sensex Today | Stock Market LIVE Updates: The markets are under immense pressure, with the Nifty index falling over 150 points, slumping towards 24,000. The Nifty Bank is down over 500 points, slumping towards 57,300. IndiGo, Cipla and and SBI are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-crude-bandhan-drl-adani-nestle-hpcl-eternal-bpcl-share-price-liveblog-19950949.htm)
- 2026-07-22 — CNBC-TV18: **Anthem Biosciences Q1 Results: Shares fall over 7% as delayed deliveries drag earnings** — Anthem Bio's Chairman, Managing Director and CEO Ajay Bhardwaj attributed the softer performance to the timing of customer deliveries rather than a slowdown in demand. — [Source](https://www.cnbctv18.com/market/anthem-biosciences-share-price-fall-q1-result-reaction-delayed-deliveries-revenue-profit-margins-outlook-cash-returns-19951098.htm)
- 2026-07-21 — FREEPRESSJOURNAL.IN: **Anthem Biosciences Reports Q1 Profit At ₹119.94 Crore, Revenue From Operations Down 31.54%** — Anthem Biosciences Limited reported a consolidated net profit of ₹119.94 crore for the quarter ended 30 June 2026. The company — [Source](https://www.freepressjournal.in/business/anthem-biosciences-reports-q1-profit-at-11994-crore-revenue-from-operations-down-3154)
- 2026-07-21 — Mint: **Raja Venkatraman recommends three stocks for 21 July** — Market expert Raja Venkatraman shares his top stock picks for 21 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-21-july-sensex-nifty-11784561114172.html)

## Business profile

**Strategic vision:** Health benefits company offering a wide range of insurance products and services.

### Business segments
- **Medical Plans:** Offers employer-sponsored, individual, and government-funded plans including Medicaid and Medicare.
- **Supplemental Benefits:** Provides dental, vision, group life, and disability insurance.
- **Pharmacy Benefits Management:** Manages pharmacy benefits through its subsidiary, IngenioRx.

### Competitive strengths
- Operates under multiple brand names, including Blue Cross Blue Shield in many states.
- Commitment to a whole health approach to improve health outcomes.
- Focus on innovation to drive progress and solutions in healthcare.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ASTERDM (Healthcare)](https://faxioms.com/stocks/asterdm) — -0.85%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/anthem
Markdown representation: https://faxioms.com/stocks/anthem?render=md